Actiphage is the first diagnostic for tuberculosis that can detect live mycobacteria in a sample of blood.
Actiphage is non-sputum based diagnostic that can detect disease progression.
To be the global leader in novel phage-based diagnostics for the diagnosis of tuberculosis.
To support the scale-up of test-and-treat campaigns for latent tuberculosis (LTI) to realise the goals of the WHO ‘End TB strategy’
TAG report reveals Actiphage only test in development for subclinical TB that directly detects mycobacteria in blood
Registered Company Address
Grosvenor St Paul’s
Grosvenor House
11 St Paul’s Square
Birmingham
B3 1RB
United Kingdom
More reasons to invest in better diagnostics for #tuberculosis 1.6 million preventable deaths and increased pressure on the few treatments available. #EndTB
Read MoreDelighted Dr Marie Roskrow is the new Chair @PBDBiotech to support development of our rapid TB diagnostic. A physician-scientist she brings expertise from @KinomicaLtd @ImevaX along with Patrys Limited, METALINEAR LIMITED, ArcticZymes Technologies
Read MoreTesting 4 tuberculosis gained renewed attention in 2022 reports @360DxNews Highlighting $30m funding @UNITAID for @FINDdx also @PBDBiotech gaining $2.9M for its blood-based test to predict which individuals with latent TB will progress to active disease
Read More
